Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duvoglustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 6/20 | 1.00 |
| ▸ | GLA known ✓ | P06280 | 4/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 4/20 | 1.00 |
| ▸ | MGAM | O43451 | 4/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 3/20 | 1.00 |
| ▸ | SI | P14410 | 3/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 1.00 |
| ▸ | LCT | P09848 | 2/20 | 1.00 |
| ▸ | GBA3 | Q9H227 | 2/20 | 1.00 |
| ▸ | MAN2B1 | O00754 | 1/20 | 1.00 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TREH | O43280 | 1/20 | 1.00 |
| ▸ | GANAB | Q14697 | 1/20 | 1.00 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duvoglustat SCHEMBL13298786 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL4619759 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL15896653 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL142573 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL10028910 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL12269503 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL24518227 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL2163281 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL13061461 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL21104989 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1030839-B1 | USE OF ALKYLATED IMINOSUGARS TO TREAT MULTIDRUG RESISTANCE | SEARLE & CO (US) | 2004-02-04 | — | — | EP | claimed |
| JP-2003506406-A | — | — | 2003-02-18 | — | — | JP | claimed |
| EP-1210082-A2 | LONG CHAIN N-ALKYL COMPOUNDS AND OXA-DERIVATIVES THEREOF AND USE AS ANTIVIRAL COMPOSITIONS | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2002-06-05 | — | — | EP | claimed |
| JP-2001508064-A | — | — | 2001-06-19 | — | — | JP | claimed |
| WO-2001010429-A2 | LONG CHAIN N-ALKYL COMPOUNDS AND OXA-DERIVATIVES THEREOF AND USE AS ANTIVIRAL COMPOSITIONS | THE CHANCELLOR, MASTERS, AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2001-02-15 | — | — | WO | claimed |
| EP-1007043-A1 | METHOD FOR TREATMENT OF CNS-INVOLVED LYSOSOMAL STORAGE DISEASES | MONSANTO COMPANY (US) | 2000-06-14 | — | — | EP | claimed |
| US-5798366-A | Method for treatment of CNS-involved lysosomal storage diseases | MONSANTO COMPANY (US) | 1998-08-25 | — | — | US | claimed |
| WO-1998030219-A1 | METHOD FOR TREATMENT OF CNS-INVOLVED LYSOSOMAL STORAGE DISEASES | MONSANTO COMPANY (US) | 1998-07-16 | — | — | WO | claimed |
| EP-3630114-B9 | MIGALASTAT FOR TREATING FABRY PATIENTS HAVING RENAL IMPAIRMENT | AMICUS THERAPEUTICS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4732901-A2 | METHODS OF TREATING FABRY DISEASE | Amicus Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12599594-B2 | Treatment of Fabry disease in ERT-naïve and ERT-experienced patients | AMICUS THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12599595-B2 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones | AMICUS THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260097027-A1 | Methods Of Treating Fabry Patients Having Renal Impairment | AMICUS THERAPEUTICS, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4356911-B1 | MIGALASTAT FOR USE IN THE TREATMENT OF FABRY DISEASE IN ERT-NAIVE AND ERT-EXPERIENCED PATIENTS | AMICUS THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-5798366-A | Method for treatment of CNS-involved lysosomal storage diseases | MONSANTO COMPANY (US) | 1998-08-25 | — | — | US | disclosed |
| WO-1998030219-A1 | METHOD FOR TREATMENT OF CNS-INVOLVED LYSOSOMAL STORAGE DISEASES | MONSANTO COMPANY (US) | 1998-07-16 | — | — | WO | disclosed |
| WO-1998030219-A1 | METHOD FOR TREATMENT OF CNS-INVOLVED LYSOSOMAL STORAGE DISEASES | MONSANTO COMPANY (US) | 1998-07-16 | — | — | WO | disclosed |
| EP-0425929-B1 | Process for the preparation of N-(2-hydroxyethyl)-2-hydroxymethyl-3,4,5-trihydroxy-piperidine and of intermediates | BAYER AG (DE) | 1995-12-06 | — | — | EP | disclosed |
| US-5071990-A | PREPARATION OF INTERMEDIATES AND THE SYNTHESIS OF N-(2-HYDROXYETHYL)-2-HYDROXYMETHYL-3,4,5-TRIHYDROXYPIPERIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 1991-12-10 | — | — | US | disclosed |
| EP-0425929-A1 | Process for the preparation of N-(2-hydroxyethyl)-2-hydroxymethyl-3,4,5-trihydroxy-piperidine and of intermediates | BAYER AG (DE) | 1991-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599595-B2 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones | GBA3, GBA1, GALC | GAA 6/4885GLA 18/4885FUCA1 57/4885 |
| US-20260097027-A1 | Methods Of Treating Fabry Patients Having Renal Impairment | GLA, GAA, MAN2B1 | GAA 2/4885GLA 1/4885FUCA1 11/4885 |
| US-12599594-B2 | Treatment of Fabry disease in ERT-naïve and ERT-experienced patients | MAN2B1, GAA, GBA1 | GAA 2/4885GLA 5/4885FUCA1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.